
    
      OUTLINE:

      Patients receive pembrolizumab IV on day 1. Treatment repeats every 21 for up to 16 cycles in
      the absence of disease progression or unacceptable toxicity. Patients also receive umbralisib
      orally (PO) daily on days 1-21 days. Cycles repeat every 21 days in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 28 days, then up to 1 year.
    
  